Literature DB >> 24118374

Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor.

Mariangela Novello1, Antonella Coli, Giuseppe Maria Della Pepa, Maurizio Martini, Francesco Doglietto, Valerio De Stefano, Silvia Bellesi, Edoardo Pescarmona, Libero Lauriola.   

Abstract

Myeloid sarcoma (MS) is a localized extra-medullary tumor mass of immature myeloid cells, arising de novo or related to acute myeloid leukemia, of which it can be a forerunner, a coinciding or late event. Less commonly, MS represents an acute blastic transformation of myelodysplastic syndromes or myeloproliferative neoplasms. This rare condition commonly consists of a proliferation of more or less immature cells with a myeloid immunophenotype, very exceptional cases showing a megakaryoblastic or erythroid differentiation. The most common localization of MS is the skin, lymph node, soft tissues and bones, but CNS involvement is exceedingly rare, with no cases reported in the sellar region. We report a 54-year-old man, affected by myeloproliferative neoplasm, JAK2 V617F-positive of 13 years duration, who acutely presented with a third cranial nerve palsy; neuroradiology documented a space-occupying lesion at the level of the sellar, upper clival and right parasellar regions, that was sub-totally removed with a trans-sphenoidal approach. The histological examination documented a proliferation of large, blastic cells, frequently multinucleated; a diagnosis of MS with megakaryoblastic differentiation, arising in a background of chronic idiopathic myelofibrosis, was suggested by immunohistochemistry, owing to CD42b, CD45, CD61 and LAT (linker for activation of T cells) positivity. In addition, homozygous JAK2 V617F mutation was detected from the myeloid sarcoma specimen. A few weeks after surgery, an acute blastic leukemic transformation occurred and, despite chemotherapy, the patient died 2 months after surgery. To the best of our knowledge, this is the first MS case with megakaryoblastic differentiation arising within the CNS.
© 2013 Japanese Society of Neuropathology.

Entities:  

Keywords:  JAK2 V617F mutation; megakaryoblastic; myelofibrosis; myeloid sarcoma; pituitary

Mesh:

Substances:

Year:  2013        PMID: 24118374     DOI: 10.1111/neup.12071

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  4 in total

1.  Myeloid Sarcoma Presented as Generalized Lymphadenopathy: Mimicking Malignant Lymphoma.

Authors:  Smeeta Gajendra; Shalini Goel; Rashi Sharma; Pratibha Dhiman; Ritesh Sachdev
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-27       Impact factor: 0.900

2.  Myeloid sarcoma of the skull base: A case report and systematic literature review.

Authors:  Prazwal Athukuri; A Basit Khan; Ron Gadot; Monira Haque; Sungho Lee; K Kelly Gallagher; Martha P Mims; Gustavo A Rivero; Andreia Barbieri; Akash J Patel; Ali Jalali
Journal:  Surg Neurol Int       Date:  2022-05-27

Review 3.  Sarcomas of the sellar region: a systematic review.

Authors:  Fernando Guerrero-Pérez; Noemi Vidal; Macarena López-Vázquez; Reinaldo Sánchez-Barrera; Juan José Sánchez-Fernández; Alberto Torres-Díaz; Nuria Vilarrasa; Carles Villabona
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

4.  Liquid Presenting as Solid: A Rare Presentation of Acute Myeloid Leukaemia as a Solid Epidural Mass.

Authors:  Varsha Gupta; Firas Ajam; Gabriella Conte; Alsadiq Al Hillan; Kadhim Al-Banaa; Vinit Singh; Michael Levitt
Journal:  Eur J Case Rep Intern Med       Date:  2020-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.